Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Ablaze Plans $100 Million Facility in Chengdu Medical City for Targeted Radiation Therapies

publication date: Aug 3, 2022

Ablaze Pharma, a targeted radiation therapy company, signed an agreement with the Wenjiang District Government of Chengdu to build a $100 million R&D and manufacturing center in Chengdu Medical City. The source of the capital was not disclosed, though it was announced during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment. Ablaze has China rights to five targeted radiation therapies from San Diego’s RayzeBio, whose radiopharmaceuticals deliver radioisotopes to tumors via the bloodstream. The therapies consist of a small peptide binder, a linker and a potent radioactive payload. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022